As part of its catabolic action in bone, parathyroid hormone (PTH) inhibits extracellular matrix mineralization. We previously showed that PTH dose-dependently induces matrix gla protein (MGP) expression in osteoblasts and this induction is at least partially responsible for PTHmediated inhibition of mineralization. Recently, we identified PKA and ERK/MAPK as the key signaling pathways involved in PTH regulation of MGP expression. The goal of this study was to further characterize the mechanism by which PTH stimulates expression of MGP. Deletion analysis of the murine Mgp gene promoter identified a PTH-responsive region between À173 bp andÀ49 bp. Using gel-mobility shift assays we found that Sp1/Sp3, and Runx2 bind to distinct sites within this region. Mutation of either the Sp or the Runx2 site reduced MGP induction by PTH, while mutation of both sites completely abolished PTH responsiveness. Overexpression of Runx2 or Sp1 activated the Mgp reporter, while Sp3 was a dose-dependent repressor of Sp1 and PTH-induced MGP expression. Collectively, these data show that PTH regulates MGP gene transcription in osteoblasts through altered activities of Sp and Runx2 transcription factors. J. Cell. Biochem. 107: 284-292, 2009. ß 2009 KEY WORDS: PARATHYROID HORMONE; MATRIX GLA PROTEIN; Sp TRANSCRIPTION FACTORS; RUNX2; OSTEOBLASTS P arathyroid hormone (PTH) action on the skeletal system is complex, with differential effects produced depending upon the mode of treatment [Tam et al., 1982] . Continuous PTH treatment induces net bone loss due to inhibition of osteoblast activity and increased bone resorption, while intermittent PTH administration causes net gain in bone due to increased bone formation [Hock and Gera, 1992; Stewart et al., 2000; Burr et al., 2001] . PTH exerts its action through the PTH1 receptor (PTH1R), a seven transmembrane domain G-protein coupled receptor expressed on the cell surface. Activation of this receptor generates multiple second messengers, which in turn activate various signaling pathways including protein kinase A (PKA), protein kinase C (PKC) and MAPK pathways [Civitelli et al., 1988; Partridge et al., 1994; Swarthout et al., 2001] . The cAMP response element binding protein (CREB), AP-1 transcription factors and Cbfa1/Runx2 are well studied PTH-responsive transcription factors in osteoblasts [Pearman et al., 1996; Koe et al., 1997; Selvamurugan et al., 2000] .
residues, through which it binds to calcium and hydroxyapatite (HA), but the exact mechanism by which MGP inhibits mineralization is not known [Hauschka et al., 1989; Roy and Nishimoto, 2002] .
We recently reported that PTH induces expression of MGP in MC3T3 osteoblasts and that MGP is a key mediator of PTH's inhibition of matrix mineralization [Gopalakrishnan et al., 2001] . Further, we showed that PTH induction of MGP expression involves both PKA and ERK/MAPK signaling pathways, and that the 748 bp murine Mgp promoter region is sufficient for transcriptional activation by PTH in MC3T3-E1 cell [Suttamanatwong et al., 2007] . Several consensus transcription factor-binding sites are present in this region of the murine Mgp promoter including AP-1, AP-2, and runt domain binding sequences [Stheneur et al., 2003] . The purpose of this study was to identify specific DNA elements in the Mgp promoter necessary for regulation by PTH and to characterize the transcription factors that elicit this regulation. We find that regulation of MGP expression by PTH is mediated through Sp and Runx2 transcription factors bound to distinct sites within the À173 to À49 region of the murine Mgp gene promoter.
MATERIALS AND METHODS

CELL CULTURE
A highly differentiating subclone of MC3T3-E1 cells was used for the studies [Wang et al., 1999; Petryk et al., 2005] . MC3T3-E1 cells express most of the known osteoblast markers and form a mineralized ECM following differentiation in ascorbic acidcontaining medium. MC-14 cells were maintained in MEM media containing 10% FBS, 1% penicillin/streptomycin, 1% non-essential amino acids and were not used beyond passage 20. PTH treatments were performed in 0.1% FBS containing MEM. For transfection experiments, MC-14 cells were plated at a density of 0.25 Â 10 5 cells/cm 2 in 35-mm dishes. For nuclear extract isolation and overexpression experiments, cells were plated at 0.50 Â 10 5 cells/cm 2 .
DNA CONSTRUCTS
The murine Mgp promoter construct, pMGP-748-luc was previously described [Suttamanatwong et al., 2007] . This plasmid contains bases À748 to þ1 of the murine Mgp gene inserted into the HindIII site of pGL3Basic (Promega) upstream of the firefly luciferase reporter gene. 5 0 -deletion constructs were created by exonuclease III digestion of the pMGP-748-luc linearized with SacI and XhoI, using the Erase-a-Base kit (Promega) as recommended by the manufacturer. Point mutations in the pMGP-luc reporter plasmids were introduced using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. The relevant sequences of the mutant reporter plasmids are provided in Table I . Plasmids pCMV-Sp1 and its empty vector, p119, were kindly provided by Dr. Robert Tjian (University of California, Berkeley, CA lysates were harvested and the luciferase activity in the cell lysates was assayed using the Dual Luciferase Reporter Kit (Promega). Transfections were performed in triplicate and normalized either to Renilla luciferase or to total protein content, due to inductive effects of Sp1 and Sp3 on the Renilla luciferase reporter.
GEL MOBILITY SHIFT ASSAYS Double-stranded oligonucleotide probes containing DNA sequence spanning from À173 to À49 of the Mgp promoter ( Fig. 2A and Table I ) were end-labeled with [a-32 P]dATP using Klenow DNA polymerase (Roche) in a reaction containing 100 ng of oligonucleotides, 5 mM each of cold G,C, and T nucleotides and 50 mCi of [a-32 P] dATP. The labeled oligonucleotide probe was purified using ProbeQuant G-50 Micro Columns (Amersham Biosciences) according to the manufacturer's instructions. Nuclear extracts (10 mg) from vehicle-or PTH-treated cells were prepared as previously published [Dignam et al., 1983] polyacrylamide gel electrophoresis in 1Â TBE for 90 min at 270 V at 48C, dried, and visualized by autoradiography.
STATISTICAL ANALYSIS
All transfection experiments were performed in triplicate and repeated at least three times. Data are represented as mean AE Standard Deviation (SD). Statistical significance was determined using Student's t-test.
RESULTS
PTH-RESPONSIVE ELEMENT(S) ARE PRESENT BETWEEN BASES À173 TO À49 BP OF THE MGP PROMOTER
We previously showed that PTH treatment increased Mgp promoter activity in a time-dependent manner, with a maximal $4-fold induction observed after 6 h [Suttamanatwong et al., 2007] . To identify the region(s) responsible for PTH-mediated transcriptional activation of MGP, we generated a series of 5' deletions of the murine Mgp promoter in the pGL3-basic luciferase reporter plasmid.
As shown in Figure 1 , the À748 bp Mgp promoter fragment was activated approximately fourfold by PTH treatment. Like the À748 bp fragment, the activity of À634, À545, and À173 bp fragments were stimulated upon PTH treatment approximately fourfold above their basal activities. In contrast, induction of the À49 bp fragment by PTH was reduced to approximately 1.5-fold above the reporter plus vehicle, representing an approximately 60% decrease in PTH-responsiveness compared with the À748 bp and À173 bp reporters. These observations suggest that element(s) necessary for PTH-responsiveness are contained within the À173 to À49 region of the Mgp promoter.
SP1 AND SP3 TRANSCRIPTION FACTORS BIND TO À63 TO À55 BP IN THE MGP PROMOTER
To identify potential transcription factor binding sites by which PTH regulates Mgp gene expression, we performed electrophoretic mobility shift assays (EMSA) using a set of overlapping doublestranded oligonucleotide probes that span the À173 to À49 bp region of the proximal Mgp promoter ( Fig. 2A) . As shown in Figure 2B , MC14 nuclear extracts contained a strong binding activity to probe 8, which spans the proximal half of the À173 to À49 region. In some experiments, treating the cells with PTH reduced binding ( Fig. 2B and data not shown), but this effect was inconsistent and its significance is unclear. To further localize the position of the binding site, we tested probes 4, 5, and 6 ( Fig. 2A) , finding that the binding site was present in probe 6 but not probes 4 or 5, indicating that the binding site is contained within the 30 nucleotides between À78 and À49. To further refine the location of the binding site, we generated a series of mutant versions of probe 6 in which three adjacent nucleotides were mutated (Table I) . Preincubation of nuclear extracts with excess unlabeled wild-type probe reduced binding to 32 P-labeled probe 6. Pre-incubation with unlabeled mutant probes M7, M7, M8 did not affect binding to labeled wild-type probe 6, while probes M5 and M9 only weakly reduced binding (Fig. 2C,D) . Further experiments confirmed that the binding activity towards 32 P-labeled mutant probes M6, M7, and M8 is highly compromised (data not shown). Sequence analysis of the region mutated in probes M6, M7, and M8 indicated that it comprises a putative Sp-transcription factor core sequence (5 0 TCCTCCCCC 3 0 ) at À63/À55 bp (underlined in Fig. 2A ).
To determine whether the binding activity in MC14 nuclear extracts reflects activity of an Sp transcription factor family member, we performed antibody supershift experiments in which we added antibodies against Sp1, Sp3 or Sp1 and Sp3 together to EMSA binding reactions with MC14 cells (Fig. 2E) . Addition of anti-Sp1 antibody produced a supershift in the upper portion of the initial mobilityshifted band. Similarly, incubation with anti-Sp3 reduced the lower portion of the original band. Incubation with both antibodies shifted or eliminated the majority of the original band. These observations led us to conclude that Sp1 and Sp3 proteins are the major proteins bound to this site in the Mgp promoter in vivo. This result was further confirmed by pre-incubation with unlabeled Sp1 consensus oligonucleotide, which efficiently blocked MC14 cell extract binding to the Mgp probes (data not shown). These data indicate that both Sp1 and Sp3 transcription factors bind to the region near À60 bp of the MGP promoter.
REGULATION OF THE MGP PROMOTER BY Sp PROTEINS AND PTH
To determine the ability of Sp1 and Sp3 to regulate the Mgp promoter, we examined the effects of overexpressed Sp1 and Sp3 on the activity of the Mgp reporters. Figure 3A shows that transfection of increasing levels of Sp1 gave a dose-dependent activation of the À173 bp Mgp reporter, while Sp3 activated the reporter less than twofold above vector alone at all doses tested. We next asked whether Sp1 and PTH could cooperate to activate the pMGP-luc reporters (Fig. 3B) . The À748 bp Mgp reporter was activated 3.3-fold above control by PTH, 2-fold by Sp1 and 12.5-fold by Sp1 and PTH together. Similarly, the À173-bp Mgp reporter was activated 3.3-fold above control by PTH, 2-fold by Sp1 and 15.8-fold by Sp1 and PTH together. These data indicate that PTH and Sp1 synergistically activate MGP expression. As Sp3 showed little ability to activate the Mgp reporters by itself (Fig. 3A) , we next determined whether Sp3 modulated activation of the À173 bp Mgp promoter by Sp1 (Fig. 3C) or PTH (Fig. 3D ). Low doses of Sp3 slightly increased promoter activity above that of Sp1 or PTH alone. However, as the amount of Sp3 increased we observed a dosedependent repression of the reporter by Sp3. Having found that Sp1 by itself activates the Mgp promoter and synergizes with PTH to strongly activate the reporter, we next asked whether the Sp binding site is necessary for activation by PTH. To this end, we introduced mutations corresponding to the Sp site M6 and M7 mutant EMSA probes (Table I) into the À748 and À173 bp MGP reporters and tested their activity and induction by PTH. Prior to treatment with PTH, the basal activity of the M6 and M7 mutant reporters was decreased by 40-70% compared to the wild-type reporters (Fig. 3E) . Likewise, the ability of PTH to activate the Sp-site mutant reporters was reduced by approximately 50% of the wildtype reporters (Fig. 3F) . Taken together, these data indicate that Sp1 contributes to basal activity and PTH-induced transcription of the Mgp promoter, while Sp3 acts as an inhibitor of MGP expression.
Runx2 BINDS TO THE PTH-RESPONSIVE REGION OF THE MGP PROMOTER
In addition to the Sp binding element in the proximal portion of the À173 to À49 bp PTH-responsive region, EMSA analysis also revealed a DNA binding activity that associated with the distal part of this region. As shown in Figure 4 , MC14 nuclear extracts contain a protein that binds to probe 7 ( Fig. 2A) , which spans the distal portion of the region, from À173 to À108 (Fig. 4A) . Gel shift analysis with probes 1, 2, and 3 localized the binding to the region from À173 to À144 contained in probe 1. Binding to these probes was not reproducibly affected by PTH treatment of the cells (Fig. 4A,C) . We next tested a set of mutant versions of probe 1 (Table I) , each with substitutions at three adjacent bases to further refine the location of the binding site. Binding to mutant probes M1, M2, M3, and M4 was strongly decreased relative to the wild-type probe, while binding to M5, M7, M8, and M9 was similar to the wildtype probe. We noted the presence of a sequence motif similar to the core OSE2 Runx2-binding element (5 0 -AACCAC) centered at nt À167 (underlined in Fig. 2A ) that was either mutated or directly adjacent to the mutated residues in probes M1 through M4. To determine whether Runx2 binds to this site, we added anti-Runx2 antibody to the binding complexes with the wild-type probes 1 or 7. Figure 4C shows that addition of anti-Runx2 antibody strongly reduced binding, indicating that Runx2 is the protein responsible for this binding activity. These data establish that Runx2 binds to a site in the distal part of PTH-responsive region of the MGP promoter.
Runx2 AND PTH COOPERATIVELY ACTIVATE MGP EXPRESSION
To determine the functional significance of Runx2 on regulation of MGP expression we compared the ability of Runx2 and PTH to activate À173 bp Mgp reporter, using the p6OSE2-luc reporter as a positive control for Runx2 transcriptional activation (Fig. 5) . As expected, Runx2 efficiently activated the p6OSE2 reporter, and although PTH had little effect on p6OSE2-luc by itself, it strongly synergized with Runx2 to activate the p6OSE2-luc reporter. The À173 bp Mgp reporter was activated between 5-and 8-fold by either Runx2 or PTH individually and approximately 15-fold by Runx2 and PTH together. To further test the significance of the Runx2 binding site on MGP expression, we introduced mutations corresponding to the mutated EMSA probes 1 M2 and M3 (Fig. 4 and Table I ) into the À173 bp MGP reporter. In each case, the ability of Runx2 or PTH to stimulate the mutant reporters was significantly diminished compared to their effect on the wild-type reporter. These data indicate that Runx2 activates the Mgp promoter and cooperates with PTH to regulate MGP expression.
LOSS OF BOTH Sp AND Runx2 SITES ABOLISHES PTH RESPONSIVENESS
Mutation of either the Sp or Runx2 binding site compromised activation of the Mgp reporters by PTH. We next examined the effect of mutating both sites together. Like the Sp-site single mutation, basal activity of the double mutant reporter was significantly reduced compared to the wild-type À173 bp reporter (Fig. 6) . The double mutant reporter was completely unresponsive to stimulation by PTH. This observation suggests that the combined activities at both the Sp and Runx2 sites are necessary for most or all of the regulation of MGP expression by PTH.
DISCUSSION
It has been reported that MGP is an important contributor to the ability of PTH to inhibit extracellular matrix mineralization in MC3T3-E1 osteoblast-like cells [Gopalakrishnan et al., 2001] . Previously, we showed that PTH treatment induces MGP mRNA and that the proximal 748 bp of the murine Mgp promoter are sufficient for transcriptional activation by PTH [Suttamanatwong et al., 2007] . We also showed that PTH induction of MGP expression involves PKA and ERK/MAPK signaling pathways [Suttamanatwong et al., 2007] . The goal of this study was to further characterize the mechanism by which PTH regulates MGP expression. To this end, we made use of 5' deletion analysis to show that the PTH-responsive region lies between À173 and À49 bp relative to the Mgp transcriptional start site. Sequence analysis of this region revealed a number of potential transcription factor binding sites. We verified protein binding to the putative Sp and Runx2 binding sites, demonstrated that Sp1 and Runx2 activate the Mgp reporters and showed that mutation of the Sp and Runx2 binding sites impaired Mgp activation.
Our antibody supershift EMSA studies indicate that Sp1 and Sp3 both bind to the Mgp promoter. The Sp (Specificity Protein) family of transcription factors, which consists of Sp1-Sp8 and the Krü pplelike factors KLF1 to KLF16 [Suske, 1999; Ganss and Jheon, 2004] , is characterized by three conserved Cys 2 His 2 zinc fingers that form the DNA-binding domain. Sp1 and Sp3 are ubiquitously expressed in Table I for details of these probes. Fig. 5 . Activation of the pMGP reporters by Runx2 and PTH. MC14 cells were transfected with wild-type (WT) and Runx2 site mutant reporters (Table I) together with Runx2 as indicated, and treated with vehicle or PTH. In parallel, cells were transfected with the p6OSE2-luc reporter as a positive control for Runx2 transcriptional activation. Luciferase activity is plotted as fold activation relative to each reporter alone. Ã P 0.02 versus wild-type reporter, same treatment. mammalian cells and Sp-binding sites are present on the promoters of genes associated with almost all cellular processes [Suske, 1999; Li et al., 2004] . Despite their ubiquity, numerous reports have indicated the importance of Sp1 and Sp3 as modulators of inducible and tissue-specific gene expression [Suske, 1999; Feng et al., 2000; Ghayor et al., 2001; Chadjichristos et al., 2002; Stains et al., 2003; Li et al., 2004] , and specific mineralized tissue defects have been noted in mice deficient in Sp proteins. The function of Sp1 in bone has not been examined as Sp1 -/-mice die around day 11 of gestation [Marin et al., 1997] . Sp3 -/-mice develop in utero without any gross abnormalities but die within 10 min of birth due to respiratory failure [Bouwman et al., 2000] . Detailed analysis of the Sp3 -/-mice revealed specific defects in tooth and bone formation. In a separate study, several skeletal malformations including mineralization defects in the vertebral bodies, sternum, skull and the craniofacial skeleton were noted in Sp3 -/-mice [Gollner et al., 2001] . The authors also noted that lack of Sp3 resulted in reduced OCN mRNA levels, while Runx2 levels were not affected. It is important to note that Sp7 (osterix), which is expressed in skeletal tissues and is important for osteoblast differentiation, is the only tissue-specific Sp protein known [Nakashima et al., 2002] . Complete absence of mineralization of bones formed by intramembranous ossification and a general deficiency of osteoblast differentiation were noted in Sp7-deficient mice [Nakashima et al., 2002] . We found that Sp1 overexpression enhanced Mgp reporter activity, whereas the effects of Sp3 overexpression were more complex, with low doses of Sp3 being activating but higher doses inhibiting transcription. Due to the extensive similarity in their zinc finger DNA-binding domains, Sp1 and Sp3 recognize and bind with similar affinity to similar GC-rich Sp-binding sites, hence numerous reports have shown that Sp3 can antagonize Sp1-mediated transcriptional activation by competing for the same binding sites [Feng et al., 2000; Ghayor et al., 2001; Chadjichristos et al., 2002; Stains et al., 2003] . Similarly, the requirement for an optimal Sp1/ Sp3 ratio in transcriptional regulation has been noted in osteoblastrelated genes such as OCN and COL2A1. Stains and coworkers showed that a Sp1/Sp3 binding element at À70 to À57 in the rat OCN promoter is necessary and sufficient to confer gap junction sensitivity [Stains et al., 2003] . The authors showed a repression of OCN transcription as a result of displacement of the stimulatory Sp1 by the inhibitory effect of Sp3 on the promoter when gap junctional communication is perturbed. Thus, alterations in the relative expression levels or DNA binding activities of Sp1 and Sp3 represent potential mechanisms for influencing their activities by PTH and other signals. The transcriptional activities of Sp1 and Sp3 are subject to regulation by modifications such as phosphorylation, glycosylation, and acetylation. Phosphorylated Sp1 and Sp3 have been reported to up-or down-regulate gene transcription. Sp1 can be phosphorylated by numerous kinases including PKA [Rohlff et al., 1997; Zheng et al., 2000] , PKC [Pal et al., 1998; Zheng et al., 2000] , and ERK/MAPK [Pal et al., 1998; Merchant et al., 1999] , the three pathways that are the main PTH responsive pathways. In addition, Sp1 can also be phosphorylated by DNA-dependent protein kinase [Jackson et al., 1990] and casein kinase II [Armstrong et al., 1997] but the sites targeted by these kinases in vivo are still unknown. Finally, the activities of Sp1 and Sp3 can be influenced by interactions with other transcription factors [reviewed by Bouwman and Philipsen, 2002] . The precise mechanism(s) by which PTH regulates Sp1 and Sp3 activities with respect to the Mgp promoter remain an area for future investigation.
In addition to Sp proteins, our data indicate that Runx2 participates in regulation of MGP expression. Previous evidence concerning a role of Runx2 in regulation of MGP expression in bone is limited. MGP was significantly upregulated in osteoblastic cells overexpressing Runx2 [Stock et al., 2004] , suggesting a potential positive role for Runx2. However, MGP was highly expressed in chondrocytes of Runx2 knockout animals [Komori et al., 1997] , suggesting that Runx2 is not required for MGP expression in cartilage. In normal vasculature, MGP is strongly expressed in endothelial and smooth muscle cells, while Runx2 is present at very low levels [Engelse et al., 2001] . During progression of vascular calcification, MGP expression is lost from calcified regions while Runx2 expression increases in atherosclerotic lesions [Engelse et al., 2001] . These data suggest antagonistic functions for Runx2 and MGP expression in the cardiovascular system.
Runx2 has been widely studied as a downstream target of PTH signaling. Our previous studies indicate that the effects of PTH on MGP expression require PKA and MEK activities, suggesting that these kinases may modulate Runx2's ability to regulate MGP. PTH has been shown to increase Runx2 transactivation of the collagenase-3 promoter through phosphorylation of the Runx2 activation domain 3 by PKA [Selvamurugan et al., 2000] . Similarly, Runx2 activity can be enhanced through phosphorylation by MEK [Xiao et al., 2002] . Another mechanism by which PTH stimulates Runx2 activity involves cooperative interactions with Runx2 and AP-1 transcription factors [D'Alonzo et al., 2002; Selvamurugan et al., 2006] . Polymorphisms at AP-1 sites in the MGP promoter are associated with altered levels of serum MGP in human subjects [Farzaneh-Far et al., 2001] . In our studies, we did not find evidence supporting AP-1 transcription factors in mediating PTH responsiveness, as mutation of potential AP-1 sites within the PTHresponsive region did not significantly alter MGP expression (data not shown). Finally, PTH has been reported to enhance Runx2-dependent transcription by stimulating Runx2 expression [Krishnan et al., 2003] . In our EMSA studies, we did not detect a change in Runx2 binding to the MGP promoter following PTH treatment (Fig. 4A and data not shown) , suggesting that the increased MGP transcription from Runx2 does not arise from overt changes in Runx2 expression or its DNA binding activity.
In summary, our data establish Sp and Runx2 transcription factors as essential mediators of PTH-stimulated MGP expression. These results provide further insight into the regulation of MGP. However, the functional significance of Sp and Runx2 regulation of MGP is not known. Determining how these transcription factors interact and regulate MGP expression is essential for understanding of how these proteins control osteoblast behavior not only during normal bone growth but also in various pathological conditions.
ACKNOWLEDGMENTS
We would like to express our gratitude to Dr. Jennifer J Westendorf and Dr. Rachel Kahler for insightful discussions and technical assistance with gel-shift analyses.
